About Syntekabio
Syntekabio is a South Korean biotechnology company that leverages artificial intelligence, big data, and supercomputing to accelerate drug discovery and development. The company operates Korea's only AI Bio Supercomputing Center and has developed multiple proprietary AI platforms including SM-ARS for small-molecule drug discovery, AB-ARS for antibody candidate discovery, NEO-ARS for neoantigen discovery and cancer vaccine design, and DEEPMATCHER for protein-compound interaction prediction. Syntekabio's technology stack combines language models with virtual screening capabilities to enable faster, more precise innovation across multiple therapeutic modalities. The company serves pharmaceutical companies, biotech firms, and research institutions globally, offering AI-powered solutions that claim to accelerate drug discovery by 3x compared to traditional methods. With over 30 patents and 30 global partnerships, Syntekabio has established itself as a significant player in the AI drug discovery space. The company generates revenue through platform licensing, collaborative research agreements, and its data center operations. Recent milestones include generating over 1 billion KRW in revenue from its DeepMatcher platform in the first half of 2025 and expanding into next-generation markets with antibody optimization and cancer vaccine platforms.
Mission & Story
Mission
Make Bio Seen - Accelerating Bio Innovation
Clinical Focus
Medical conditions and clinical areas addressed by Syntekabio.
Who It Serves
Milestones & Awards
Recent Milestones
Generated 1.2 billion KRW revenue in first half of 2025 with over 1 billion from DeepMatcher platform; received patent registration for eco-friendly termite-inspired data center design; expanding into next-generation markets with antibody optimization and cancer vaccine discovery platforms; targeting accelerated revenue growth with next-gen platforms
Awards & Recognition
Operates Korea's only AI Bio Supercomputing Center
Company Details
- Headquarters
- South Korea
Work here?
Claim this listing to update company information and connect with our audience.
Claim This ListingOfficial Sources
Similar Companies in this Market
View all 64 →
A2A Pharmaceuticals
AI-driven pharmaceutical company focused on discovering and developing novel drug candidates using computational biology and machine learning.
AbCellera
AbCellera uses AI and machine learning to discover and develop antibody-based therapeutics and vaccines.
Absci
Absci uses AI-powered computational biology and machine learning to accelerate drug discovery and optimize therapeutic proteins and antibodies.
Adaptyv Bio
11-50 employees
Adaptyv Bio operates the world's fastest protein validation lab, providing automated experimental testing services for AI-designed proteins. The company enables protein engineers to validate binding, expression, and thermostability of novel protein designs through a fully automated platform with 3-week turnaround times.
Aitia
Aitia is a drug discovery and development company leveraging AI and computational biology to identify novel therapeutic targets and accelerate drug development.
Anagenex
Anagenex is a biotechnology company focused on drug discovery and development. The company appears to operate in the pharmaceutical research space, though specific details about their technology platform, therapeutic areas, and target markets are not available from the provided content.
Aqemia
Aqemia is a drug discovery company advancing next-generation medicines using generative AI and deep physics. The company combines AI-augmented discovery with computational chemistry to develop novel therapeutics at scale.
Arctoris
51-200 employees
Arctoris is a Partnership Research Organisation (PRO) providing automated wet lab biology R&D and data generation services for biotech, techbio, and pharma companies through its Ulysses® robotic platform.
Data Accuracy Notice: Company information on HealthAI Central is compiled from public sources and updated regularly. While we strive for accuracy, details such as funding figures, employee counts, and product offerings may change. We recommend verifying critical information directly with the company before making business decisions.